目的 分析2020—2023年宜昌市中心人民医院新型抗肿瘤药物的使用情况和发展趋势，为该类药物的临床合理使用和规范化管理提供参考。方法 收集宜昌市中心人民医院2020年1月1日—2023年12月31日新型抗肿瘤药物的相关用药信息，对品种数、销售金额、用药频度（DDDs）、限定日费用（DDC）、药品排序比（B/A）等指标进行回顾性统计分析。结果 2020—2023年新型抗肿瘤药物的品种数呈波动态势，总销售金额和总DDDs逐年增长，30种药物的DDC下降。贝伐珠单抗、奥希替尼和曲妥珠单抗的销售金额均位居前3位。信迪利单抗的DDDs增长速度最快，在2023年排名升至第1位，DDC值从2020年270.76降至2023年的102.86，连续4年B/A≥1。奥希替尼和阿美替尼的临床使用频率明显增加，2023年DDDs分别排名第2、3位。伊马替尼和吉非替尼使用频率较高、DDC值低，B/A在4年内均大于2，同步性好，利用度高。结论 宜昌市中心人民医院新型抗肿瘤药物使用量逐渐增加，药品价格下降，符合国家政策要求及肿瘤治疗的发展趋势。

Objective To analyze the application situation and development tendency of novel antitumor drugs in Yichang Central People’s Hospital from 2020 to 2023, and to provide references for the rationally clinical application and standardized management of these drugs. Methods The drug information of novel antitumor drugs in Yichang Central People’s Hospital from January 1, 2020 to December 31, 2023 was collected, and the indexes such as variety number, consumption sum, DDDs, DDC, B/A were retrospectively analyzed. Results From 2020 to 2023, the number of novel antitumor drugs fluctuates, the total sales sum and total DDDs increase year by year, and the DDC of 30 drugs decreases. The consumption sum of bevacizumab, osimertinib, and trastuzumab ranked the top 3. The DDDs of sintilimab increased the fastest, rising to the first place in 2023, and the DDC value decreased from 270.76 in 2020 to 102.86 in 2023, with B/A≥1 for 4 consecutive years. The frequency of clinical use of osimertinib and almonertinib has increased significantly, ranking second and third respectively in DDDs in 2023. Imatinib and gefitinib had high use frequency, low DDC value, B/A greater than 2 in 4 years, good synchronization and high availability. Conclusion The usage of novel antitumor drugs in Yichang Central People’s Hospital are gradually increasing, and drug prices are decreasing, which is in line with national policy requirements and the development trend of tumor treatment.

R979.1

武汉药学会2022年度医院药学学科发展孵化项目（WHPA2022000009）